Bristol-Myers Squibb Co (BMY) Shares Sold by BTIM Corp.

BTIM Corp. reduced its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 1.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,490 shares of the biopharmaceutical company’s stock after selling 255 shares during the period. BTIM Corp.’s holdings in Bristol-Myers Squibb were worth $1,086,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in BMY. Blue Chip Partners Inc. increased its stake in Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 17 shares during the last quarter. Keel Point LLC boosted its position in shares of Bristol-Myers Squibb by 0.3% in the first quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock valued at $342,000 after buying an additional 18 shares during the last quarter. Staley Capital Advisers Inc. boosted its position in shares of Bristol-Myers Squibb by 0.3% in the first quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock valued at $379,000 after buying an additional 24 shares during the last quarter. Shayne & CO. LLC boosted its position in shares of Bristol-Myers Squibb by 0.7% in the first quarter. Shayne & CO. LLC now owns 4,017 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 27 shares during the last quarter. Finally, Founders Capital Management LLC boosted its position in shares of Bristol-Myers Squibb by 0.7% in the first quarter. Founders Capital Management LLC now owns 4,097 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 29 shares during the last quarter. Institutional investors own 69.79% of the company’s stock.

Shares of Bristol-Myers Squibb Co (NYSE:BMY) traded up 1.56% during mid-day trading on Tuesday, reaching $57.18. The company had a trading volume of 2,554,194 shares. Bristol-Myers Squibb Co has a 52 week low of $46.01 and a 52 week high of $64.77. The stock has a 50 day moving average of $55.55 and a 200-day moving average of $54.50. The company has a market capitalization of $93.77 billion, a price-to-earnings ratio of 20.88 and a beta of 1.17.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. The company had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb had a return on equity of 25.24% and a net margin of 17.92%. Bristol-Myers Squibb’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.69 earnings per share. On average, analysts expect that Bristol-Myers Squibb Co will post $2.97 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, August 1st. Shareholders of record on Friday, July 7th were given a dividend of $0.39 per share. The ex-dividend date was Wednesday, July 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.77%. Bristol-Myers Squibb’s dividend payout ratio is currently 56.73%.

ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb Co (BMY) Shares Sold by BTIM Corp.” was reported by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/bristol-myers-squibb-co-bmy-shares-sold-by-btim-corp/1409406.html.

Several research analysts have issued reports on the company. BidaskClub cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Leerink Swann dropped their target price on Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating on the stock in a research report on Friday, July 28th. Piper Jaffray Companies set a $60.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Thursday, July 27th. Vetr raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.33 target price on the stock in a research report on Wednesday, July 26th. Finally, BMO Capital Markets reissued an “underperform” rating and issued a $47.00 target price (down from $51.00) on shares of Bristol-Myers Squibb in a research report on Wednesday, July 26th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Bristol-Myers Squibb presently has an average rating of “Hold” and an average price target of $63.33.

In other Bristol-Myers Squibb news, Director Theodore R. Samuels II purchased 6,000 shares of the stock in a transaction on Wednesday, August 2nd. The shares were bought at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the transaction, the director now owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.23% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co and related companies with our FREE daily email newsletter.

 


Latest News

Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras


Leave a Reply

 
© 2006-2017 BBNS.